tbuckley/cabot-search huggingface dataset:
Proinflammatory CD20 <sup>+</sup> T cells contribute to CNS-directed autoimmunity
Authors: Jasmin Ochs, Nitzan Nissimov, Sebastian Torke, Marie Freier, Katja Grondey, Julian Koch, Matthias Klein, Linda Feldmann, Cathrin Gudd, Tobias Bopp, Silke Häusser-Kinzel, Martin S. Weber
Journal: Science Translational Medicine (2022)

The origin and function of CD20 + T cells are poorly understood. Here, we characterized CD20 + T cells in mice and humans and investigated how they are affected by anti-CD20 antibody treatment. We report that murine CD20 + T cells are unable to endogenously express the B cell lineage marker CD20; the development of CD20 + T cells in rodents requires the presence of CD20-expressing B cells. Our results demonstrated that both murine and human T cells acquire CD20 from B cells via trogocytosis while being activated by an antigen-presenting B cell. In patients with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE), expression of CD20 on T cells is associated with an up-regulation of activation markers, proinflammatory cytokines, and adhesion molecules, suggesting high pathogenic potential. Supporting this hypothesis, CD20 + T cells expand during active EAE in rodents; furthermore, adoptive transfer of CD20 + T cells into EAE-diseased mice worsened histological and clinical severity. Of direct therapeutic relevance, we demonstrate that the exclusive therapeutic elimination of CD20 + T cells effectively ameliorates EAE, independent of B cells. The results support the hypothesis that CD20 + T cells arise upon B cell–T cell interaction and that depletion of CD20 + T cells might contribute to the success of anti-CD20 antibody therapies in MS and other inflammatory disorders.
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications
Authors: Umar Mehraj, Umar Mushtaq, Manzoor A. Mir, Afnan Saleem, Muzafar A. Macha, Mohammad Nadeem Lone, Abid Hamid, Mohammed A. Zargar, Syed Mudasir Ahmad, Nissar Ahmad Wani
Journal: Seminars in Cancer Biology (2022)
CLO22-061: c-MET Alteration in Patients With Metastasized Colorectal Carcinoma – An Evaluation of Methods of Detection, Clinical Impact and Discussion of c-MET as Potential Therapeutic Target
Authors: Amelie Lueders, Annalen Bleckmann, Tim Beißbarth, Hans-Ulrich Schildhaus
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CLO22-061: c-MET Alteration in Patients With Metastasized Colorectal Carcinoma – An Evaluation of Methods of Detection, Clinical Impact and Discussion of c-MET as Potential Therapeutic Target" published on 31 Mar 2022 by National Comprehensive Cancer Network.
TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A NATIONAL TREND ANALYSIS
Authors: Adithya Thomas Mathews, Kapil Hemant Painter, Mohamed Hamed, Hamza Lodhi, Ramez Morcos, Anand Desai, Houman Khalili, Brijeshwar Singh Maini
Journal: Journal of the American College of Cardiology (2022)
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study
Authors: Bridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, Catalina Barcelo, Stephen D Woolley, Harilal Patel, Stacey Llewellyn, Azrin N Abd-Rahman, Sunil Sharma, Mukul Jain, Ashok Ghoghari, Ilaria Di Resta, Aline Fuchs, Ioanna Deni, Tomas Yeo, Sachel Mok, David A Fidock, Stephan Chalon, Jörg J Möhrle, Deven Parmar, James S McCarthy, Kevinkumar Kansagra
Journal: The Lancet Infectious Diseases (2022)
LATE DEVICE-RELATED THROMBUS OF A PERCUTANEOUS PATENT FORAMEN OVALE CLOSURE DEVICE
Authors: Alexander Levstik, Moghniuddin Mohammed, Mohamed Eid, Abdul Jawwad Samdani, James Evans, Mallory Balmer-Swain, Matthew Funderburk, Naila Choudhary, Jeremiah Peter Depta
Journal: Journal of the American College of Cardiology (2022)
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp>/<scp>PRAAS</scp>, <scp>SAVI</scp>, and <scp>AGS</scp>
Authors: Kader Cetin Gedik, Lovro Lamot, Micol Romano, Erkan Demirkaya, David Piskin, Sofia Torreggiani, Laura A. Adang, Thais Armangue, Kathe Barchus, Devon R. Cordova, Yanick J. Crow, Russell C. Dale, Karen L. Durrant, Despina Eleftheriou, Elisa M. Fazzi, Marco Gattorno, Francesco Gavazzi, Eric P. Hanson, Min Ae Lee‐Kirsch, Gina A. Montealegre Sanchez, Bénédicte Neven, Simona Orcesi, Seza Ozen, M. Cecilia Poli, Elliot Schumacher, Davide Tonduti, Katsiaryna Uss, Daniel Aletaha, Brian M. Feldman, Adeline Vanderver, Paul A. Brogan, Raphaela Goldbach‐Mansky
Journal: Arthritis & Rheumatology (2022)

Objective Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome‐associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy (SAVI), and Aicardi‐Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of “points to consider” to improve diagnosis, treatment, and long‐term monitoring of patients with these rare diseases. Methods Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates, and an allied health care professional formulated research questions for a systematic literature review. Then, based on literature, Delphi questionnaires, and consensus methodology, “points to consider” to guide patient management were developed. Results The Task Force devised consensus and evidence‐based guidance of 4 overarching principles and 17 points to consider regarding the diagnosis, treatment, and long‐term monitoring of patients with the autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI, and AGS. Conclusion These points to consider represent state‐of‐the‐art knowledge to guide diagnostic evaluation, treatment, and management of patients with CANDLE/PRAAS, SAVI, and AGS and aim to standardize and improve care, quality of life, and disease outcomes.
ACCURACY OF RAPID CARDIOVASCULAR MAGNETIC RESONANCE ASSESSMENT OF LEFT VENTRICULAR FUNCTION
Authors: Leila Mabudian, Ralph B. D’Agostino, Jennifer H. Jordan, Madalyn B. Martin, Julia A. Fleshman, Teresa Crotts, Amy Ladd, Kathryn E. Weaver, Glenn J. Lesser, Mary Helen Hackney, W. Gregory Hundley
Journal: Journal of the American College of Cardiology (2022)
Cigarette smoking is a secondary cause of folliculin loss
Authors: Xiuying Li, Yandong Lai, Zachary Lane, Hilary Strollo, Kazuya Tanimura, John C Sembrat, Chunbin Zou, Michael M Myerburg, Mauricio Rojas, Steven Shapiro, Yu Jiang, Toru Nyunoya
Journal: Thorax (2022)

Background Birt-Hogg-Dubé syndrome (BHD) is a clinical syndrome manifesting with cystic lung disease and pneumothorax. Features of BHD result from the loss-of-function mutations of the folliculin ( FLCN ) gene. Chronic obstructive pulmonary disease (COPD), characterised by an irreversible airflow limitation, is primarily caused by cigarette smoking. Objective Given that COPD often shares structural features with BHD, we investigated the link between COPD, cigarette smoke (CS) exposure and FLCN expression. Methods We measured the expression of FLCN in human COPD lungs and CS-exposed mouse lungs, as well as in CS extract (CSE)-exposed immortalised human airway epithelial cells by immunoblotting. Results We found that the lung FLCN protein levels in smokers with COPD and CS exposure mice exhibit a marked decrease compared with smokers without COPD and room air exposure mice, respectively. We confirmed CS induced degradation of FLCN in immortalised human bronchial epithelial Beas-2B cells via ubiquitin proteasome system. Further, siRNA targeting FLCN enhanced CSE-induced cytotoxicity. By contrast, FLCN overexpression protected cells from CSE-induced cytotoxicity. We found that FBXO23, the ubiquitin E3 ligase subunit, specifically binds to and targets FLCN for degradation. Inhibition of ATM (ataxia‐telangiectasia mutated) attenuated CSE induced FLCN degradation, suggesting a role of ATM in FLCN proteolysis. We further confirmed that the mutant of major FLCN phosphorylation site serine 62A is resistant to CSE-induced degradation and cytotoxicity. Conclusions Our study demonstrates that CS exposure is a secondary cause of FLCN deficiency due to the enhanced proteolysis, which promoted airway epithelial cell death.
22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases
Authors: J. Tobias, M. Drinić, S. Högler, A. Schmid, E. Garner-Spitzer, L. Kenner, M. Kundi, C.C. Zielinski, U. Wiedermann
Journal: Annals of Oncology (2022)
DIRECT ORAL ANTICOAGULANTS COMPARED WITH WARFARIN FOR THE TREATMENT OF LEFT VENTRICULAR THROMBI
Authors: Omar Aldaas, Kim Ji-Hyun, Samhita Palakodeti, Apoorva Mylavarapu, Praneet Mylavarapu, Andrew Kahn, Jonathan Chong Hsu, Gordon Ho, Fred T. Han, Anthony N. DeMaria
Journal: Journal of the American College of Cardiology (2022)
Can Adalimumab Reduce the Extent of Hidradenitis Suppurativa Surgery?
Authors: Philippe Guillem, Christelle Perat, Virginie Vlaeminck-Guillem
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Arthritis &amp; Rheumatology: “<scp>Mid‐Term</scp>” Report
Authors: Daniel H. Solomon, Richard Bucala, Mariana J. Kaplan, Peter A. Nigrovic
Journal: Arthritis & Rheumatology (2022)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
CLO22-039: Clinical Implication of Perineural Invasion in Patients Treated With Radical Prostatectomy for Prostate Cancer
Authors: José Alfonso Leiva Centeno, Patricio Orbe Villota, Juan José de Benito, Leonardo Víctor Tavip, María Belén Leithold, Sandro Mario Varea, Pedro Gustavo Minuzzi
Journal: Journal of the National Comprehensive Cancer Network (2022)
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
Authors: Alexander Spira, Laura Liao, Xiaolei Zhou, Bintu Sherif, Lei Chen, David Ungar, Eric Yu, John Radford, Mehdi Hamadani
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Urinary culture sensitivity after a single empirical antibiotic dose for upper or febrile urinary tract infection: A prospective multicentre observational study
Authors: Gregor John, Eric Mugnier, Etienne Pittet, Dominique Marianne Staehli, Olivier Clerc, Alain Foguena Kenfak, Andreas Konasch, Reto Lienhard, Daniel Genné
Journal: Clinical Microbiology and Infection (2022)

ObjectivesUrinary culture sensitivity after antibiotics administration is unknown. This study aimed to describe the diagnostic sensitivity of urine cultures from patients' first, second, and third micturition samples after a single dose of empirical antibiotics given for upper and/or febrile urinary tract infections, as well as searched for factors influencing diagnostic sensitivity over time.MethodsWe collected consecutive urine samples from adult patients with an upper or febrile urinary tract infection diagnosed at four secondary hospital emergency rooms. One sample was collected before a first dose of empirical antibiotic treatment and up to three samples were collected from consecutive postadministration micturition. The main outcome was the number of positive cultures growing uropathogens with ≥103 colony forming units (CFUs) for men and ≥104 for women. Identical analyses were performed for any identified CFU and ≥105 CFU cut-off points. Time between antibiotic administration and first negative urinary culture was noted, which could have been at the time of any of the three postantibiotic urine samples. We used a Cox regression analysis for age- and sex-adjusted analyses.ResultsA total of 86 of 87 patients' preantibiotic cultures (99%) were positive compared with 26 of 75 (35%; p < 0.001), 15 of 50 (30%; p < 0.001), and 1 of 15 (7%; p < 0.001) of the first, second, and third postantibiotic samples, respectively, and missing 14 of 21 (67%), 13 of 17 (76%), and 7 of 7 (100%) of uropathogens with antibiotic resistance, respectively. The times needed for 25%, 50%, and 75% of cultures to be negative were 1.5, 2.9, and 9 hours, respectively, after antibiotic administration. Older age, male sex, non-Escherichia coli pathogens, urinary tract disease, comorbidity burdens, and urinary catheters prolonged time to negative culture, but were not significantly associated after adjustment. Uropathogens were found at ≥105 CFU in 15 of 75 (20%), 7 of 50 (14%), and 0 of 15 (0%) of the three postantibiotic micturition samples, respectively, and in any identified CFU in 48 of 75 (64%), 23 of 50 (46%), and 1 of 15 (7%), respectively.ConclusionUrinary culture sensitivity decreases rapidly after administering antibiotics.
IN-STENT RESTENOSIS OF A BARE-METAL STENT IN A PATIENT WITH HEMOPHILIA A
Authors: Phillip Lim, Anoshia Raza, Inderjit Singh, Parul Kakar, Mohamad Soud, Uzair Ashraf, Christine M. Gerula, Alfonso H. Waller, Julius M. Gardin, Marc Klapholz
Journal: Journal of the American College of Cardiology (2022)
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
Authors: Haiping Jiang, Xiongfei Yu, Ning Li, Mei Kong, Zhimin Ma, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He, Zhongqi Li, Yimin Lu, Jing Zhang, Kui Zhao, Yafei Zhang, Nong Xu, Ziran Li, Ying Liu, Yan Wang, Yisen Wang, Lisong Teng
Journal: Journal for ImmunoTherapy of Cancer (2022)

Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However, the role of anti-programmed cell death protein-1 treatment in the neoadjuvant setting remains unclear. This phase 2 study aimed to evaluate sintilimab plus CapeOx as a neoadjuvant regimen in patients with advanced resectable G/GEJ adenocarcinoma. Eligible patients with resectable G/GEJ adenocarcinoma stage cT3-4NanyM0 were enrolled. Patients received neoadjuvant treatment with sintilimab (3 mg/kg for cases &lt;60 kg or 200 mg for those ≥60 kg on day 1) plus CapeOx (oxaliplatin at 130 mg/m 2 on D1 and capecitabine at 1000 mg/m 2 two times per day on D1–D14) every 21 days, for three cycles before surgical resection, followed by adjuvant treatment with three cycles of CapeOx with the same dosages after surgical resection. The primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included objective response rate, tumor regression grade per Becker criteria, survival and safety. As of July 30, 2020, 36 patients were enrolled. Totally 7 (19.4%) patients had GEJ cancer, and 34 (94.4%) patients were clinical stage III cases. A total of 35 (97.2%) patients completed three cycles of neoadjuvant treatment, and 1 patients received two cycles due to adverse events. All patients underwent surgery and the R0 resection rate was 97.2%. In this study, pCR and major pathological response were achieved in 7 (19.4%, 95% CI: 8.8% to 35.7%; 90% CI: 10.7% to 33.1%) and 17 (47.2%, 95% CI: 31.6% to 64.3%) patients, respectively. Thirty-one patients received adjuvant treatment. By December 20, 2021, three patients died after disease relapse, and two patients were alive with relapse. Median disease-free survival (DFS) and overall survival (OS) were not reached. The 1-year DFS and OS rates were 90.3% (95% CI: 80.4% to 100.0%) and 94.1% (95% CI: 86.5% to 100.0%), respectively. The most common (&gt;1 patient) grade 3 treatment-related adverse events during neoadjuvant treatment were anemia and neutropenia (n=5 each, 13.9%). No serious adverse events (AEs) or grade 4–5 AEs were observed. Sintilimab plus oxaliplatin/capecitabine showed promising efficacy with encouraging pCR rate and good safety profile in the neoadjuvant setting. This combination regimen might present a new option for patients with locally advanced, resectable G/GEJ adenocarcinoma. Trial registration; NCT04065282 .
RACIAL AND SOCIOECONOMIC DIFFERENCES IN PATTERNS OF GROWTH IN USE OF THE PERCUTANEOUS MICROAXIAL LEFT VENTRICULAR ASSIST DEVICE IN CARDIOGENIC SHOCK
Authors: Zaid Almarzooq, Siyan Chen, Yang Song, Tianyu Sun, Eric Alexander Secemsky, Duane S. Pinto, Robert W. Yeh, Richard A., Susan F. Smith
Journal: Journal of the American College of Cardiology (2022)
THREE TIME LOSER OR THIRD TIME’S THE CHARM? OUTCOME OF REPEATED PERCUTANEOUS CORONARY INTERVENTION FOR RECURRENT RESTENOSIS AFTER TWO LAYERS OF DRUG-ELUTING STENTS
Authors: Michael P. Savage, Meiqi Luo, Goutham Ravipati, David L. Fischman, Melissa M. McCarey, Nicholas J. Ruggiero, Alec Vishnevsky, Paul Walinsky
Journal: Journal of the American College of Cardiology (2022)
PREDICTORS OF MORTALITY FOR SEVERE ATRIAL FIBRILLATION-RELATED FUNCTIONAL TRICUSPID REGURGITATION
Authors: Lin Fei Perryn Ng, Edgar Tay, Siew Pang Chan, Wern Miin Soo, William KF Kong, Kian Keong Poh, Raymond Ching-Chiew Wong, Tiong Cheng Yeo, Lieng H. Ling, Robin Cherian
Journal: Journal of the American College of Cardiology (2022)
Unscrambling cancer genomes via integrated analysis of structural variation and copy number
Authors: Charles Shale, Daniel L. Cameron, Jonathan Baber, Marie Wong, Mark J. Cowley, Anthony T. Papenfuss, Edwin Cuppen, Peter Priestley
Journal: Cell Genomics (2022)

Complex somatic genomic rearrangements and copy number alterations are hallmarks of nearly all cancers. We have developed an algorithm, LINX, to aid interpretation of structural variant and copy number data derived from short-read, whole-genome sequencing. LINX classifies raw structural variant calls into distinct events and predicts their effect on the local structure of the derivative chromosome and the functional impact on affected genes. Visualizations facilitate further investigation of complex rearrangements. LINX allows insights into a diverse range of structural variation events and can reliably detect pathogenic rearrangements, including gene fusions, immunoglobulin enhancer rearrangements, intragenic deletions, and duplications. Uniquely, LINX also predicts chained fusions that we demonstrate account for 13% of clinically relevant oncogenic fusions. LINX also reports a class of inactivation events that we term homozygous disruptions that may be a driver mutation in up to 9% of tumors and may frequently affect
NATIONAL TRENDS OF USE OF DIGOXIN IN ATRIAL FIBRILLATION: DATA FROM NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS 2006-2015)
Authors: Abdul Mannan Khan Minhas, Abu Baker Sheikh, Ahmed Hassaan Qavi, Shakeel Jamal, Muhammad Hisham Khan Wazir, Muhammad Osama Muslim, Marat Fudim, Khurram Nasir
Journal: Journal of the American College of Cardiology (2022)
Childhood factors associated with suicidal ideation among South African youth: A 28-year longitudinal study of the Birth to Twenty Plus cohort
Authors: Massimiliano Orri, Marilyn N. Ahun, Sara Naicker, Sahba Besharati, Linda M. Richter
Journal: PLoS Medicine (2022)

Background Although early life factors are associated with increased suicide risk in youth, there is a dearth of research on these associations for individuals growing up in disadvantaged socioeconomic contexts, particularly in low- and middle-income countries (LMICs). We documented the association between individual, familial, and environmental factors in childhood with suicidal ideation among South African youth. Methods and findings We used data from 2,020 participants in the Birth to Twenty Plus (Bt20+) study, a South African cohort following children born in Soweto, Johannesburg from birth (1990) to age 28 years (2018). Suicidal ideation was self-reported at ages 14, 17, 22, and 28 years, and the primary outcome of interest was suicidal ideation reported at any age. We assessed individual, familial, and socioeconomic characteristics at childbirth and during infancy, adverse childhood experiences (ACEs) between ages 5 and 13 years, and externalizing and internalizing problems between 5 and 10 years. We estimated odds ratios (ORs) of suicidal ideation for individuals exposed to selected childhood factors using logistic regression. Lifetime suicidal ideation was reported by 469 (23.2%) participants, with a 1.7:1 female/male ratio. Suicidal ideation rates peaked at age 17 and decreased thereafter. Socioeconomic adversity, low birth weight, higher birth order (i.e., increase in the order of birth in the family: first, second, third, fourth, or later born child), ACEs, and childhood externalizing problems were associated with suicidal ideation, differently patterned among males and females. Socioeconomic adversity (OR 1.13, CI 1.01 to 1.27, P = 0.031) was significantly associated with suicidal ideation among males only, while birth weight (OR 1.20, CI 1.02 to 1.41, P = 0.03), ACEs (OR 1.11, CI 1.01 to 1.21, P = 0.030), and higher birth order (OR 1.15, CI 1.07 to 1.243, P &lt; 0.001) were significantly associated with suicidal ideation among females only. Externalizing problems in childhood were significantly associated with suicidal ideation among both males (OR 1.23, 1.08 to 1.40, P = 0.002) and females (OR 1.16, CI 1.03 to 1.30, P = 0.011). Main limitations of the study are the high attrition rate (62% of the original sample was included in this analysis) and the heterogeneity in the measurements of suicidal ideation. Conclusions In this study from South Africa, we observed that early life social and environmental adversities as well as childhood externalizing problems are associated with increased risk of suicidal ideation during adolescence and early adulthood.
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization
Authors: Luc Djoussé, Nancy R. Cook, Eunjung Kim, Joseph Walter, Omar T. Al-Ramady, Heike Luttmann-Gibson, Christine M. Albert, Samia Mora, Julie E. Buring, J. Michael Gaziano, JoAnn E. Manson
Journal: JACC Heart Failure (2022)